Ligand validation:2HU4

G39: (3R,4R,5S)-4-(acetylamino)-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid

G39 is a Ligand Of Interest in 2HU4 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2HU4_G39_A_800	100%	7%	0.023	0.996	2.69	2.1	6	6	0	0	100%	1
2HU4_G39_B_801	100%	7%	0.022	0.996	2.65	2.11	7	5	0	0	100%	1
2HU4_G39_E_804	100%	8%	0.028	0.994	2.67	2.06	8	5	0	0	100%	1
2HU4_G39_G_806	100%	7%	0.024	0.994	2.7	2.06	6	5	0	0	100%	1
2HU4_G39_C_802	100%	8%	0.03	0.993	2.63	2.09	7	6	0	0	100%	1
2HU4_G39_F_805	100%	8%	0.029	0.994	2.66	2.06	7	5	0	0	100%	1
2HU4_G39_H_807	100%	7%	0.031	0.994	2.81	2.11	7	5	0	0	100%	1
2HU4_G39_D_803	100%	7%	0.032	0.992	2.75	2.11	7	7	0	0	100%	1
3CL0_G39_A_800	87%	53%	0.071	0.942	0.75	1.06	-	1	0	0	100%	1
5NZ4_G39_B_503	86%	52%	0.083	0.952	0.89	0.96	1	1	0	0	100%	1
4B7R_G39_D_801	85%	7%	0.09	0.956	2.13	2.72	5	3	0	0	100%	1
5NZF_G39_A_503	84%	45%	0.089	0.95	1	1.12	2	2	0	0	100%	1
4B7J_G39_A_1470	82%	10%	0.084	0.939	2.18	2.15	6	4	0	0	100%	1
6HEB_G39_A_522	94%	53%	0.07	0.969	0.73	1.06	1	1	0	0	100%	1
4HZZ_G39_A_509	93%	8%	0.065	0.96	2.61	2.03	6	7	0	0	100%	1
4MWW_G39_A_513	93%	5%	0.066	0.959	3.25	2.09	5	8	0	0	100%	1
6HG5_G39_D_510	92%	48%	0.072	0.963	0.85	1.14	1	2	0	0	100%	1
7XVU_G39_B_501	91%	3%	0.072	0.96	4.56	1.43	8	5	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.